Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    MACULAR DEGENERATION, AGE-RELATED, 8
Show Display Options
Rank Status Study
1 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
2 Withdrawn Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
Condition: Age Related Macular Degeneration
Interventions: Drug: Bevasiranib;   Drug: ranibizumab
3 Terminated
Has Results
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
Condition: Macular Degeneration
Interventions: Drug: bevasiranib;   Drug: ranibizumab

Indicates status has not been verified in more than two years